Cannabis-based experimental therapies currently under research, in particular Epidiolex, show significant promise to treat therapy-resistant epilepsy, including Dravet syndrome, according to a recent review. The report “Investigational cannabinoids in seizure disorders, what have we learned thus far?” published in the journal Expert Opinion in Investigational Drugs, provides an overview on the recent advances of investigational cannabinoids (cannabis-derived […]

RESTON, Va. (PRWEB) June 11, 2018 MMJ International Holding’s, the premier medical cannabis research company that is advancing the science of medical marijuana through patient clinical research, announced today MMJ’s filing of an Investigational New Drug (IND) application with the FDA to initiate clinical trials assessing the company’s THC/CBD pharmaceutical compounds for treating and/or preventing […]

Botanix Pharmaceuticals achieved treatment success using its cannabidiol-based BTX 1204 in 35% of its atopic dermatitis patients during its phase 1b clinical trial. Dermatology company Botanix Pharmaceuticals (ASX: BOT) has published successful results from its phase 1b patient study looking into the safety profile of its cannabidiol-based BTX 1204 transdermal gel that aims to treat […]

RESTON, Va., June 11, 2018 /PRNewswire-PRWeb/ — MMJ International Holding’s, the premier medical cannabis research company that is advancing the science of medical marijuana through patient clinical research, announced today MMJ’s filing of an Investigational New Drug (IND) application with the FDA to initiate clinical trials assessing the company’s THC/CBD pharmaceutical compounds for treating and/or preventing […]

Botanix Pharmaceuticals achieved treatment success using its cannabidiol-based BTX 1204 in 35% of its atopic dermatitis patients during its phase 1b clinical trial. Dermatology company Botanix Pharmaceuticals (ASX: BOT) has published successful results from its phase 1b patient study looking into the safety profile of its cannabidiol-based BTX 1204 transdermal gel that aims to treat […]

According to a report from Brightfield Group, the global cannabis market is currently valued at about USD 7.7 Billion and is projected to reach USD 31.4 Billion by 2021. The United States accounts for about 90 percent of the whole market, but its domination of the industry is anticipated to decline to approximately 57 percent […]

Editorial: Lyn Chesna, Managing EditorAdvertising: Maureen Dwyer Liberti, Vice President, Group PublisherGreg Pessagno, National Account ManagerKim Kleinberg, National Account ManagerProduction: Dawn Flook, Director of Production ServicesCirculation: Jackie Ott, Circulation ManagerWebmaster: Webmaster … read more at: https://www.ptcommunity.com/wire/gw-pharmaceuticals-present-goldman-sachs-39th-annual-global-healthcare-conference

LONDON and CARLSBAD, Calif., June 06, 2018 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (NASDAQ:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that GW management will present at the Goldman Sachs 39th Annual Global Healthcare Conference on Wednesday, June […]

Dravet syndrome (DS), also known as epilepsy with polymorphic seizures and polymorphic epilepsy in infancy (PMEI), is a severe and rare genetic dysfunction of the brain (epileptic encephalopathy). It usually begins in first year of life and remains throughout lifetime. Children suffering from dravet syndrome suffer from different type of seizures namely, myoclonic seizures, tonic-clonic […]

WEDNESDAY, May 16, 2018 (HealthDay News) — Less appears to be more when it comes to treating epilepsy with the marijuana extract cannabidiol, a new clinical trial suggests. … read more at: http://www.philly.com/philly/health/topics/HealthDay733982_20180516_Low_Dose_of_CBD_Liquid_Eases_Epilepsy_Seizures__Study.html